ClinicalTrials.gg
CompletedNCT03031782Updated Aug 15, 2022Results posted

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

A Phase 3 interventional study of secukinumab and placebo in Juvenile Psoriatic Arthritis and Enthesitis-related Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 31 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-08-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Arthritis, Juvenile by Novartis — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Juvenile · Novartis.

Enrollment
4th of 12
86 · median 43
Started
2017
the only one that year
Phase 3
9 of 18
none open now
Registered
9th of 18
by date

Among the 18 studies in Arthritis, Juvenile by Novartis, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 9 in phase 3, and was the 9th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

6 of the 18 studies in Arthritis, Juvenile by Novartis are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Arthritis, Juvenile by Novartis, or all of them as a file.
02

Study summary

This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study was divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2

Read the detailed description

TP1: All eligible subjects entered TP1 to receive 12-weeks of open-label secukinumab at a dose predicted to achieve secukinumab serum levels equivalent to adults administered a 150 mg dose regimen. Secukinumab was administered s.c. weekly for the first 4 weeks (Baseline, Weeks 1, 2, 3, 4) and then every 4 weeks thereafter. Clinical response (JIA ACR 30) was assessed at Week 12. Responders advanced to TP2 and non-responders exited the trial (early termination visit and entered into the Post-treatment follow-up period).

TP2: Subjects who were a responder (JIA ACR 30) at Week 12 entered the double-blind withdrawal TP2 and were randomized 1:1 to either secukinumab or placebo on that visit and then every 4 weeks, until either experiencing a disease flare or completion of TP2. TP2 was event driven and was planned to be closed when 33 subjects experienced a disease flare as per JIA definition. Alternatively, the study could be closed when all subjects reached the total study duration of 104 Weeks and therefore subjects who did not experience a disease flare remained in TP2 for the duration of the study and completed the study without entering into TP3

TP3: Subjects experiencing a disease flare in TP2 immediately entered TP3 to receive openlabel secukinumab every 4 weeks until total study duration of 104 weeks for that subject was achieved.

Post-treatment follow-up: The post-treatment follow-up period (lasting 12 weeks from the last study drug administration) was required for all subjects, unless they qualified and entered the secukinumab extension trial. All subjects were expected to participate in the post-treatment follow up period, except for those entering the extension study.

03

Conditions studied

  • Juvenile Psoriatic Arthritis
  • Enthesitis-related Arthritis

Keywords

  • JIA
  • JPsA
  • ERA
  • Secukinumab
  • ILAR
  • Arthritis
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of Enthesitis-related arthritis (ERA) or Juvenile psoriatic arthritis (JPsA) according to the International League of Associations for Rheumatology (ILAR) classification criteria of at least 6 months duration.
  2. Active disease (ERA or JPsA) defined as having both:

    • at least 3 active joints
    • at least 1 site of active enthesitis at baseline or documented by history.
  3. Inadequate response (at least 1 month) or intolerance to at least 1 nonsteroidal anti-inflammatory drugs(NSAID)
  4. Inadequate response (at least 2 months) or intolerance to at least 1 Disease-modifying antirheumatic drugs (DMARD)
  5. No concomitant use of agents such as disease-modifying and/or drugs.

Exclusion criteria

Exclusion Criteria:

  1. Patients fulfilling any ILAR diagnostic JIA category other than ERA or JPsA.
  2. Patients who have ever received biologic immunomodulating agents
  3. Patients taking any non-biologic DMARD except for MTX (or sulfasalazine for ERA patients only).
  4. Patients with active uncontrolled inflammatory bowel disease or active uncontrolled uveitis.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Treatment Period 2 - active

    secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1

    Drug: secukinumab

  • Placebo comparator
    Treatment Period 2 - placebo

    placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1

    Other: placebo

Interventions

  • secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.

    Also known as: AIN457

  • Otherplacebo

    Matched placebo to AIN457 for use in the double blind Treatment Period 2

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing a Flare During Treatment Period 2

    Survival analysis of time to flare in treatment period 2 (TP2) FAS2 Subjects are either ERA or JPsA

    Time frame: From Week 12 until max Week 104

Secondary outcomes

  1. Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - by JIA Category

    Summary of JIA ACR 30/50/70/90/100 for all subjects and each JIA category - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)

    Time frame: baseline, week 12

  2. Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - Total

    Summary of JIA ACR 30/50/70/90/100 for all subjects - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)

    Time frame: baseline, week 12

  3. Percent Change From Baseline for JIA ACR Core Components in TP1

    Summary of JIA ACR core components for all subjects and each JIA category - Treatment period 1 Negative percent change indicates improvement Physician global assessment of disease activity (VAS mm) 0 (no disease activity) - 100 (very severe); Parent or subject global assessment of overall well-being (VAS mm) 0 (very well) - 100 (very poor); CHAQ (Childhood Health Assessment Questionnaire) 0 - 3 (most severe); Number of joints with active arthritis 0 - 73; Number of joints with limited range of motion 0 - 69.

    Time frame: baseline, week 12

  4. Percent Change in C-reactive Protein Standardized Value (mg/L)

    Median Percent Change from baseline for C-reactive protein standardized value (mg/L)

    Time frame: baseline, week 12

  5. Change From Baseline Juvenile Arthritis Disease Activity Score (JADAS) Score

    JADAS change from baseline for all subjects in Treatment period 1. JADAS-27 (Juvenile Arthritis Disease Activity Score in 27 joints) ranges from 0 to 57 and JADAS-71 ranges from 0 to 101 (higher scores indicate more disease activity).

    Time frame: 12 weeks

  6. Change From Baseline in Total Enthesitis Events - TP1 (FAS1)

    Enthesitis swollen joint count range is 0-16. Zero is worst, and 16 is best A total of 16 entheseal sites were assessed for the presence or absence of tenderness of enthesitis. This is the mean (SD) enthesitis count (range 0-16) for FAS subjects A zero score means no enthesitis, so a zero score is better for the patient

    Time frame: Baseline and week 12

  7. Change From Baseline in Total Dactylitis Count

    Summary of total dactylitis count for all subjects - TP1 (FAS1) Total dactylitis count ranges from 0 to 20. A zero score means no dactylitis, so a zero score is better for the patient

    Time frame: baseline, week 12

  8. Number of Participants With Anti-secukinumab Anitbodies

    Blood samples for immunogenicity (anti-AIN457 antibodies) were taken pre-dose at the scheduled time points. In addition, if a subject discontinued from the study at any time, he/she provided a sample at the last visit. All blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. An Electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.

    Time frame: 104 weeks

  9. Secukinumab Serum Concentration

    Summary of pharmacokinetic concentrations - Treatment period 1

    Time frame: baseline, week 12

  10. Number of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1)

    Summary of inactive disease status for all subjects - TP1 (FAS1) Clinical inactive disease definition was adapted from the JIA ACR criteria. All were required to be met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA ≤15 min

    Time frame: week 12

07

Results

Posted Aug 15, 2022

Participant flow

86 subjects entered TP1

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneAIN457 in TP1AIN457 in TP 2Placebo in TP2AIN457 in TP3Placebo in TP 3
Started860000
Completed830000
Not completed30000
Withdrew: Lack of efficacy30000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneAIN457 in TP1AIN457 in TP 2Placebo in TP2AIN457 in TP3Placebo in TP 3
Started03738021
Completed03136016
Not completed06205
Withdrew: Physician decision01003
Withdrew: Lack of efficacy01001
Withdrew: Withdrawal by subject03001
Withdrew: Adverse event01200
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneAIN457 in TP1AIN457 in TP 2Placebo in TP2AIN457 in TP3Placebo in TP 3
Started000110
Completed000100
Not completed00010
Withdrew: Withdrawal by subject00010

Outcome measures

PrimaryNumber of Participants Experiencing a Flare During Treatment Period 2

Survival analysis of time to flare in treatment period 2 (TP2) FAS2 Subjects are either ERA or JPsA

Time frame:
From Week 12 until max Week 104
Reported as:
Count of participants · Participants
Number of Participants Experiencing a Flare During Treatment Period 2
ParticipantsAIN457 in Treatment Period 2Placebo in TP2
Number of Participants Experiencing a Flare During Treatment Period 21021
Statistical analysis
  • AIN457 in Treatment Period 2 vs Placebo in TP2 · Log Rank · p = <0.001 · Cox proportional hazard: 0.28 · 95% CI 0.13 to 0.63Hazard ratios and associated 95% confidence intervals are based on a Cox proportional hazards model with treatment and analysis factors
SecondaryPercent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - by JIA Category

Summary of JIA ACR 30/50/70/90/100 for all subjects and each JIA category - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)

Time frame:
baseline, week 12
Reported as:
Number · percent of participants
Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - by JIA Category
percent of participantsAIN457 in Treatment Period 1 - ERAAIN457 in Treatment Periiod 1 - JPsA
ACR 3086.3 (73.1 to 93.8)96.9 (82.0 to 99.8)
ACR 5080.4 (66.5 to 89.7)96.9 (82.0 to 99.8)
ACR 7066.7 (52.0 to 78.9)75.0 (56.2 to 87.9)
ACR 9033.3 (21.1 to 48.0)50.0 (32.2 to 67.8)
ACR 10027.5 (16.3 to 42.0)21.9 (9.9 to 40.4)
SecondaryPercent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - Total

Summary of JIA ACR 30/50/70/90/100 for all subjects - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)

Time frame:
baseline, week 12
Reported as:
Number · percent of participants
Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - Total
percent of participantsAIN457 in Treatment Period 1 - TOTAL
ACR 3090.4 (81.4 to 95.4)
ACR 5086.7 (77.1 to 92.9)
ACR 7069.9 (58.7 to 79.2)
ACR 9039.8 (29.4 to 51.1)
ACR 10025.3 (16.7 to 36.2)
SecondaryPercent Change From Baseline for JIA ACR Core Components in TP1

Summary of JIA ACR core components for all subjects and each JIA category - Treatment period 1 Negative percent change indicates improvement Physician global assessment of disease activity (VAS mm) 0 (no disease activity) - 100 (very severe); Parent or subject global assessment of overall well-being (VAS mm) 0 (very well) - 100 (very poor); CHAQ (Childhood Health Assessment Questionnaire) 0 - 3 (most severe); Number of joints with active arthritis 0 - 73; Number of joints with limited range of motion 0 - 69.

Time frame:
baseline, week 12
Reported as:
Mean · percent change
Percent Change From Baseline for JIA ACR Core Components in TP1
percent changeAIN457 in Treatment Period 1
physician global assessment of disease activity-77.4 ± 22.67
parent/subject global assessment of overall well-being-53.1 ± 58.43
functional ability (CHAQ)-53.776 ± 70.5034
number of joints with active arthritis-79.3 ± 34.86
number of joints with limited range of motion-72.5 ± 38.19
SecondaryPercent Change in C-reactive Protein Standardized Value (mg/L)

Median Percent Change from baseline for C-reactive protein standardized value (mg/L)

Time frame:
baseline, week 12
Reported as:
Median · percent change
Percent Change in C-reactive Protein Standardized Value (mg/L)
percent changeAIN457 in Treatment Period 1
Percent Change in C-reactive Protein Standardized Value (mg/L)-13.587 ± 227.6901
SecondaryChange From Baseline Juvenile Arthritis Disease Activity Score (JADAS) Score

JADAS change from baseline for all subjects in Treatment period 1. JADAS-27 (Juvenile Arthritis Disease Activity Score in 27 joints) ranges from 0 to 57 and JADAS-71 ranges from 0 to 101 (higher scores indicate more disease activity).

Time frame:
12 weeks
Reported as:
Mean · score
Change From Baseline Juvenile Arthritis Disease Activity Score (JADAS) Score
scoreAIN457 in Treatment Period 1
JADAS-27-10.487 ± 7.2262
JADAS-71-13.403 ± 9.7300
SecondaryChange From Baseline in Total Enthesitis Events - TP1 (FAS1)

Enthesitis swollen joint count range is 0-16. Zero is worst, and 16 is best A total of 16 entheseal sites were assessed for the presence or absence of tenderness of enthesitis. This is the mean (SD) enthesitis count (range 0-16) for FAS subjects A zero score means no enthesitis, so a zero score is better for the patient

Time frame:
Baseline and week 12
Reported as:
Mean · Number of enthesitis events
Change From Baseline in Total Enthesitis Events - TP1 (FAS1)
Number of enthesitis eventsAIN457 in Treatment Period 1
Change From Baseline in Total Enthesitis Events - TP1 (FAS1)-1.8 ± 2.31
SecondaryChange From Baseline in Total Dactylitis Count

Summary of total dactylitis count for all subjects - TP1 (FAS1) Total dactylitis count ranges from 0 to 20. A zero score means no dactylitis, so a zero score is better for the patient

Time frame:
baseline, week 12
Reported as:
Mean · Number of dactylitis events
Change From Baseline in Total Dactylitis Count
Number of dactylitis eventsAIN457 in Treatment Period 1
Change From Baseline in Total Dactylitis Count-0.8 ± 1.83
SecondaryNumber of Participants With Anti-secukinumab Anitbodies

Blood samples for immunogenicity (anti-AIN457 antibodies) were taken pre-dose at the scheduled time points. In addition, if a subject discontinued from the study at any time, he/she provided a sample at the last visit. All blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. An Electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.

Time frame:
104 weeks
Reported as:
Count of participants · Participants
Number of Participants With Anti-secukinumab Anitbodies
ParticipantsAIN457 in Treatment Period 1AIN457 in Treatment Period 2 - ActivePlacebo TP2
Number of Participants With Anti-secukinumab Anitbodies000
SecondarySecukinumab Serum Concentration

Summary of pharmacokinetic concentrations - Treatment period 1

Time frame:
baseline, week 12
Reported as:
Mean · mcg/mL
Secukinumab Serum Concentration
mcg/mLAIN457 in Treatment Period 1
<50 kg30.9 ± 12.9
>=50 kg34.6 ± 11.2
SecondaryNumber of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1)

Summary of inactive disease status for all subjects - TP1 (FAS1) Clinical inactive disease definition was adapted from the JIA ACR criteria. All were required to be met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA ≤15 min

Time frame:
week 12
Reported as:
Number · partcipants
Number of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1)
partcipantsAIN457 in Treatment Period 1
Number of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1)30 (26.1 to 47.5)

Adverse events

Collected over Adverse events (AEs) were collected from the time patient provided informed consent until the end of study. Serious Adverse Events (SAEs) were collected after the patient provided informed consent and until 12 weeks after last administered dose of study treatment or 30 days after the subject has stopped study participation (whichever is later). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 in Entire Treatment Period0/48 (0%)7/48 (14.6%)44/48 (91.7%)
Placebo in TP20/38 (0%)4/38 (10.5%)35/38 (92.1%)
Total0/86 (0%)11/86 (12.8%)79/86 (91.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventAIN457 in Entire Treatment PeriodPlacebo in TP2Total
Acute sinusitisInfections and infestations0/481/381/86
PneumoniaInfections and infestations0/481/381/86
Postoperative wound infectionInfections and infestations0/481/381/86
TonsillitisInfections and infestations0/481/381/86
Juvenile psoriatic arthritisMusculoskeletal and connective tissue disorders0/481/381/86
Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders0/481/381/86
Crohn's diseaseGastrointestinal disorders1/480/381/86
Food poisoningGastrointestinal disorders1/480/381/86
AppendicitisInfections and infestations1/480/381/86
FolliculitisInfections and infestations1/480/381/86
Most frequent other events
Showing 10 of 230
Most frequent other events
EventAIN457 in Entire Treatment PeriodPlacebo in TP2Total
NasopharyngitisInfections and infestations16/4811/3827/86
Upper respiratory tract infectionInfections and infestations10/489/3819/86
DiarrhoeaGastrointestinal disorders11/486/3817/86
NauseaGastrointestinal disorders11/488/3819/86
ArthralgiaMusculoskeletal and connective tissue disorders8/484/3812/86
CoughRespiratory, thoracic and mediastinal disorders8/485/3813/86
Abdominal painGastrointestinal disorders2/486/388/86
PyrexiaGeneral disorders6/486/3812/86
HeadacheNervous system disorders6/486/3812/86
Oropharyngeal painRespiratory, thoracic and mediastinal disorders7/485/3812/86

Baseline characteristics

Safety Set included subjects who received any treatment. TP1 = 86, TP2 = 75

Age, Categorical
Age, Categorical(Participants)All Participants
AIN457 in Treatment Period 1 — <=18 years86
AIN457 in Treatment Period 1 — Between 18 and 65 years0
AIN457 in Treatment Period 1 — >=65 years0
AIN457 in Treatment Period 2 — <=18 years37
AIN457 in Treatment Period 2 — Between 18 and 65 years0
AIN457 in Treatment Period 2 — >=65 years0
placebo in TP2 — <=18 years38
placebo in TP2 — Between 18 and 65 years0
placebo in TP2 — >=65 years0
Age, Continuous
Age, Continuous(years)All Participants
AIN457 in Treatment Period 1 - JIA Category: ERA13.7 ± 2.62
AIN457 in Treatment Period 1 - JIA Category: JPsA12.2 ± 3.66
AIN457 in Treatment Period 2 - JIA Category: ERA14 ± 2.46
AIN457 in Treatment Period 2 - JIA Category: JPsA13.1 ± 3.14
Placebo in TP2- JIA Category: ERA13 ± 2.94
Placebo in TP2 - JIA Category JPsA10.6 ± 3.70
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
AIN457 in Treatment Period 1 - JIA Category: ERA — Female11
AIN457 in Treatment Period 1 - JIA Category: ERA — Male41
AIN457 in Treatment Period 1 -JIA Category: JPsA — Female18
AIN457 in Treatment Period 1 -JIA Category: JPsA — Male16
AIN457 in Treatment Period 2 - JIA Category: ERA — Female4
AIN457 in Treatment Period 2 - JIA Category: ERA — Male18
AIN457 in Treatment Period 2 -JIA Category: JPsA — Female9
AIN457 in Treatment Period 2 -JIA Category: JPsA — Male6
Placebo in TP2 - JIA Category: ERA — Female4
Placebo in TP2 - JIA Category: ERA — Male18
Placebo in TP2 - JIA Category: JPsA — Female7
Placebo in TP2 - JIA Category: JPsA — Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
AIN457 in Treatment Period 1 - JIA Category: ERA — American Indian or Alaska Native0
AIN457 in Treatment Period 1 - JIA Category: ERA — Asian0
AIN457 in Treatment Period 1 - JIA Category: ERA — Native Hawaiian or Other Pacific Islander0
AIN457 in Treatment Period 1 - JIA Category: ERA — Black or African American0
AIN457 in Treatment Period 1 - JIA Category: ERA — White51
AIN457 in Treatment Period 1 - JIA Category: ERA — More than one race0
AIN457 in Treatment Period 1 - JIA Category: ERA — Unknown or Not Reported1
AIN457 in Treatment Period 1 - JIA Category: JPsA — American Indian or Alaska Native0
AIN457 in Treatment Period 1 - JIA Category: JPsA — Asian1
AIN457 in Treatment Period 1 - JIA Category: JPsA — Native Hawaiian or Other Pacific Islander0
AIN457 in Treatment Period 1 - JIA Category: JPsA — Black or African American0
AIN457 in Treatment Period 1 - JIA Category: JPsA — White31
AIN457 in Treatment Period 1 - JIA Category: JPsA — More than one race0
AIN457 in Treatment Period 1 - JIA Category: JPsA — Unknown or Not Reported2
AIN457 in Treatment Period 2 - JIA Category: ERA — American Indian or Alaska Native0
AIN457 in Treatment Period 2 - JIA Category: ERA — Asian0
AIN457 in Treatment Period 2 - JIA Category: ERA — Native Hawaiian or Other Pacific Islander0
AIN457 in Treatment Period 2 - JIA Category: ERA — Black or African American0
AIN457 in Treatment Period 2 - JIA Category: ERA — White22
AIN457 in Treatment Period 2 - JIA Category: ERA — More than one race0
AIN457 in Treatment Period 2 - JIA Category: ERA — Unknown or Not Reported0
AIN457 in Treatment Period 2 - JIA Category: JPsA — American Indian or Alaska Native0
AIN457 in Treatment Period 2 - JIA Category: JPsA — Asian0
AIN457 in Treatment Period 2 - JIA Category: JPsA — Native Hawaiian or Other Pacific Islander0
AIN457 in Treatment Period 2 - JIA Category: JPsA — Black or African American14
AIN457 in Treatment Period 2 - JIA Category: JPsA — White0
AIN457 in Treatment Period 2 - JIA Category: JPsA — More than one race0
AIN457 in Treatment Period 2 - JIA Category: JPsA — Unknown or Not Reported1
Placebo in TP2 - JIA Category: ERA — American Indian or Alaska Native0
Placebo in TP2 - JIA Category: ERA — Asian0
Placebo in TP2 - JIA Category: ERA — Native Hawaiian or Other Pacific Islander0
Placebo in TP2 - JIA Category: ERA — Black or African American0
Placebo in TP2 - JIA Category: ERA — White21
Placebo in TP2 - JIA Category: ERA — More than one race0
Placebo in TP2 - JIA Category: ERA — Unknown or Not Reported1
Placebo in TP2 - JIA Category: JPsA — American Indian or Alaska Native0
Placebo in TP2 - JIA Category: JPsA — Asian0
Placebo in TP2 - JIA Category: JPsA — Native Hawaiian or Other Pacific Islander1
Placebo in TP2 - JIA Category: JPsA — Black or African American0
Placebo in TP2 - JIA Category: JPsA — White14
Placebo in TP2 - JIA Category: JPsA — More than one race0
Placebo in TP2 - JIA Category: JPsA — Unknown or Not Reported1
08

Study locations

31 sites
  • Novartis Investigative Site
    Los Angeles, California 90027, United States
  • Novartis Investigative Site
    Boise, Idaho 83702, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45229, United States
  • Novartis Investigative Site
    Portland, Oregon 97232, United States
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Laeken, 1020, Belgium
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 22081, Germany
  • Novartis Investigative Site
    Saint Augustin, 53757, Germany
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Krakow, 31503, Poland
  • Novartis Investigative Site
    Ekaterinburg, 620149, Russian Federation
  • Novartis Investigative Site
    Moscow, 119991, Russian Federation
  • Novartis Investigative Site
    Saint-Petersburg, 194100, Russian Federation
  • Novartis Investigative Site
    Voronezh, 394036, Russian Federation
  • Novartis Investigative Site
    Cape Town, 7925, South Africa
  • Novartis Investigative Site
    Panorama, 7500, South Africa
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Istanbul, Halkali 34303, Turkey
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Istanbul, 34766, Turkey
  • Novartis Investigative Site
    Bristol, BS2 8BJ, United Kingdom
  • Novartis Investigative Site
    Glasgow, G51 4TF, United Kingdom
  • Novartis Investigative Site
    Liverpool, L12 2AP, United Kingdom
  • Novartis Investigative Site
    London, WC1N 3JH, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, Chasnyk VG, Hufnagel M, Zuber Z, Schulert G, Ozen S, Rakhimyanova A, Ramanan A, Scott C, Sozeri B, Zholobova E, Martin R, Zhu X, Whelan S, Pricop L, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023 Jan;82(1):154-160. doi: 10.1136/ard-2022-222849. Epub 2022 Aug 12. PubMed 35961761 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Oct 2020, 40 months.

Results were first posted in Aug 2022, 1 year 10 months after primary completion. A results delay was requested in May 2020.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Jan 26, 2017
StartActual
May 23, 2017
Primary completionActual
Oct 7, 2020
CompletionActual
Nov 9, 2020
Results delay requested
May 19, 2020
Results first posted
Aug 15, 2022
Last update
Aug 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03031782
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
May 23, 2017
Primary completion
Oct 7, 2020
Completion
Nov 9, 2020
Results posted
Aug 15, 2022
Last update
Aug 15, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion